NSCLC: Immunotherapy Beyond Progression – OncLive
|
NSCLC: Immunotherapy Beyond Progression
OncLive Benjamin Besse, MD, PhD: I think treatment beyond progression is not an issue of immunotherapy, it’s a general concern. It may be a good strategy with some TKIs, sometimes with chemotherapy, and with immunotherapy. It’s always the same. There is not 1 … |
|
Sanofi drops Voyager’s phase 2/3 Parkinson’s gene therapy
FierceBiotech Sanofi has walked away from the Parkinson’s gene therapy covered by its $845 million alliance with Voyager Therapeutics. The decision gives Voyager the full global rights to VY-AADC but leaves it without a partner as it gears up for a pivotal global … |
|
Sanofi drops Voyager’s phase 2/3 Parkinson’s gene therapy
FierceBiotech Sanofi has walked away from the Parkinson’s gene therapy covered by its $845 million alliance with Voyager Therapeutics. The decision gives Voyager the full global rights to VY-AADC but leaves it without a partner as it gears up for a pivotal global … |
|
Sanofi drops Voyager’s phase 2/3 Parkinson’s gene therapy
FierceBiotech Sanofi has walked away from the Parkinson’s gene therapy covered by its $845 million alliance with Voyager Therapeutics. The decision gives Voyager the full global rights to VY-AADC but leaves it without a partner as it gears up for a pivotal global … |